Human IGF-I propeptide A promotes articular chondrocyte biosynthesis and employs glycosylation-dependent heparin binding

Shuiliang Shi, Brian J. Kelly, Congrong Wang, Ken Klingler, Albert Chan, George J. Eckert, Stephen Trippel

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background Insulin-like growth factor I (IGF-I) is a key regulator of chondrogenesis, but its therapeutic application to articular cartilage damage is limited by rapid elimination from the repair site. The human IGF-I gene gives rise to three IGF-I propeptides (proIGF-IA, proIGF-IB and proIGF-IC) that are cleaved to create mature IGF-I. In this study, we elucidate the processing of IGF-I precursors by articular chondrocytes, and test the hypotheses that proIGF-I isoforms bind to heparin and regulate articular chondrocyte biosynthesis. Methods Human IGF-I propeptides and mutants were overexpressed in bovine articular chondrocytes. IGF-I products were characterized by ELISA, western blot and FPLC using a heparin column. The biosynthetic activity of IGF-I products on articular chondrocytes was assayed for DNA and glycosaminoglycan that the cells produced. Results Secreted IGF-I propeptides stimulated articular chondrocyte biosynthetic activity to the same degree as mature IGF-I. Of the three IGF-I propeptides, only one, proIGF-IA, strongly bound to heparin. Interestingly, heparin binding of proIGF-IA depended on N-glycosylation at Asn92 in the EA peptide. To our knowledge, this is the first demonstration that N-glycosylation determines the binding of a heparin-binding protein to heparin. Conclusion The biosynthetic and heparin binding abilities of proIGF-IA, coupled with its generation of IGF-I, suggest that proIGF-IA may have therapeutic value for articular cartilage repair. General significance These data identify human pro-insulin-like growth factor IA as a bifunctional protein. Its combined ability to bind heparin and augment chondrocyte biosynthesis makes it a promising therapeutic agent for cartilage damage due to trauma and osteoarthritis.

Original languageEnglish (US)
Pages (from-to)567-575
Number of pages9
JournalBiochimica et Biophysica Acta - General Subjects
Volume1862
Issue number3
DOIs
StatePublished - Mar 1 2018

Fingerprint

Glycosylation
Biosynthesis
Chondrocytes
Insulin-Like Growth Factor I
Heparin
Joints
Cartilage
Articular Cartilage
Repair
Chondrogenesis
Somatomedins
Glycosaminoglycans
Osteoarthritis
Protein Isoforms

Keywords

  • Biosynthesis
  • Chondrocyte
  • E peptide
  • Glycosylation
  • Heparin-binding protein
  • IGF-I propeptide
  • Insulin-like growth factor (IGF)
  • Protein processing

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology

Cite this

Human IGF-I propeptide A promotes articular chondrocyte biosynthesis and employs glycosylation-dependent heparin binding. / Shi, Shuiliang; Kelly, Brian J.; Wang, Congrong; Klingler, Ken; Chan, Albert; Eckert, George J.; Trippel, Stephen.

In: Biochimica et Biophysica Acta - General Subjects, Vol. 1862, No. 3, 01.03.2018, p. 567-575.

Research output: Contribution to journalArticle

Shi, Shuiliang ; Kelly, Brian J. ; Wang, Congrong ; Klingler, Ken ; Chan, Albert ; Eckert, George J. ; Trippel, Stephen. / Human IGF-I propeptide A promotes articular chondrocyte biosynthesis and employs glycosylation-dependent heparin binding. In: Biochimica et Biophysica Acta - General Subjects. 2018 ; Vol. 1862, No. 3. pp. 567-575.
@article{2e81bfbbc62446deb85487ed7afd422b,
title = "Human IGF-I propeptide A promotes articular chondrocyte biosynthesis and employs glycosylation-dependent heparin binding",
abstract = "Background Insulin-like growth factor I (IGF-I) is a key regulator of chondrogenesis, but its therapeutic application to articular cartilage damage is limited by rapid elimination from the repair site. The human IGF-I gene gives rise to three IGF-I propeptides (proIGF-IA, proIGF-IB and proIGF-IC) that are cleaved to create mature IGF-I. In this study, we elucidate the processing of IGF-I precursors by articular chondrocytes, and test the hypotheses that proIGF-I isoforms bind to heparin and regulate articular chondrocyte biosynthesis. Methods Human IGF-I propeptides and mutants were overexpressed in bovine articular chondrocytes. IGF-I products were characterized by ELISA, western blot and FPLC using a heparin column. The biosynthetic activity of IGF-I products on articular chondrocytes was assayed for DNA and glycosaminoglycan that the cells produced. Results Secreted IGF-I propeptides stimulated articular chondrocyte biosynthetic activity to the same degree as mature IGF-I. Of the three IGF-I propeptides, only one, proIGF-IA, strongly bound to heparin. Interestingly, heparin binding of proIGF-IA depended on N-glycosylation at Asn92 in the EA peptide. To our knowledge, this is the first demonstration that N-glycosylation determines the binding of a heparin-binding protein to heparin. Conclusion The biosynthetic and heparin binding abilities of proIGF-IA, coupled with its generation of IGF-I, suggest that proIGF-IA may have therapeutic value for articular cartilage repair. General significance These data identify human pro-insulin-like growth factor IA as a bifunctional protein. Its combined ability to bind heparin and augment chondrocyte biosynthesis makes it a promising therapeutic agent for cartilage damage due to trauma and osteoarthritis.",
keywords = "Biosynthesis, Chondrocyte, E peptide, Glycosylation, Heparin-binding protein, IGF-I propeptide, Insulin-like growth factor (IGF), Protein processing",
author = "Shuiliang Shi and Kelly, {Brian J.} and Congrong Wang and Ken Klingler and Albert Chan and Eckert, {George J.} and Stephen Trippel",
year = "2018",
month = "3",
day = "1",
doi = "10.1016/j.bbagen.2017.11.017",
language = "English (US)",
volume = "1862",
pages = "567--575",
journal = "Biochimica et Biophysica Acta - General Subjects",
issn = "0304-4165",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Human IGF-I propeptide A promotes articular chondrocyte biosynthesis and employs glycosylation-dependent heparin binding

AU - Shi, Shuiliang

AU - Kelly, Brian J.

AU - Wang, Congrong

AU - Klingler, Ken

AU - Chan, Albert

AU - Eckert, George J.

AU - Trippel, Stephen

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Background Insulin-like growth factor I (IGF-I) is a key regulator of chondrogenesis, but its therapeutic application to articular cartilage damage is limited by rapid elimination from the repair site. The human IGF-I gene gives rise to three IGF-I propeptides (proIGF-IA, proIGF-IB and proIGF-IC) that are cleaved to create mature IGF-I. In this study, we elucidate the processing of IGF-I precursors by articular chondrocytes, and test the hypotheses that proIGF-I isoforms bind to heparin and regulate articular chondrocyte biosynthesis. Methods Human IGF-I propeptides and mutants were overexpressed in bovine articular chondrocytes. IGF-I products were characterized by ELISA, western blot and FPLC using a heparin column. The biosynthetic activity of IGF-I products on articular chondrocytes was assayed for DNA and glycosaminoglycan that the cells produced. Results Secreted IGF-I propeptides stimulated articular chondrocyte biosynthetic activity to the same degree as mature IGF-I. Of the three IGF-I propeptides, only one, proIGF-IA, strongly bound to heparin. Interestingly, heparin binding of proIGF-IA depended on N-glycosylation at Asn92 in the EA peptide. To our knowledge, this is the first demonstration that N-glycosylation determines the binding of a heparin-binding protein to heparin. Conclusion The biosynthetic and heparin binding abilities of proIGF-IA, coupled with its generation of IGF-I, suggest that proIGF-IA may have therapeutic value for articular cartilage repair. General significance These data identify human pro-insulin-like growth factor IA as a bifunctional protein. Its combined ability to bind heparin and augment chondrocyte biosynthesis makes it a promising therapeutic agent for cartilage damage due to trauma and osteoarthritis.

AB - Background Insulin-like growth factor I (IGF-I) is a key regulator of chondrogenesis, but its therapeutic application to articular cartilage damage is limited by rapid elimination from the repair site. The human IGF-I gene gives rise to three IGF-I propeptides (proIGF-IA, proIGF-IB and proIGF-IC) that are cleaved to create mature IGF-I. In this study, we elucidate the processing of IGF-I precursors by articular chondrocytes, and test the hypotheses that proIGF-I isoforms bind to heparin and regulate articular chondrocyte biosynthesis. Methods Human IGF-I propeptides and mutants were overexpressed in bovine articular chondrocytes. IGF-I products were characterized by ELISA, western blot and FPLC using a heparin column. The biosynthetic activity of IGF-I products on articular chondrocytes was assayed for DNA and glycosaminoglycan that the cells produced. Results Secreted IGF-I propeptides stimulated articular chondrocyte biosynthetic activity to the same degree as mature IGF-I. Of the three IGF-I propeptides, only one, proIGF-IA, strongly bound to heparin. Interestingly, heparin binding of proIGF-IA depended on N-glycosylation at Asn92 in the EA peptide. To our knowledge, this is the first demonstration that N-glycosylation determines the binding of a heparin-binding protein to heparin. Conclusion The biosynthetic and heparin binding abilities of proIGF-IA, coupled with its generation of IGF-I, suggest that proIGF-IA may have therapeutic value for articular cartilage repair. General significance These data identify human pro-insulin-like growth factor IA as a bifunctional protein. Its combined ability to bind heparin and augment chondrocyte biosynthesis makes it a promising therapeutic agent for cartilage damage due to trauma and osteoarthritis.

KW - Biosynthesis

KW - Chondrocyte

KW - E peptide

KW - Glycosylation

KW - Heparin-binding protein

KW - IGF-I propeptide

KW - Insulin-like growth factor (IGF)

KW - Protein processing

UR - http://www.scopus.com/inward/record.url?scp=85037628621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037628621&partnerID=8YFLogxK

U2 - 10.1016/j.bbagen.2017.11.017

DO - 10.1016/j.bbagen.2017.11.017

M3 - Article

C2 - 29174671

AN - SCOPUS:85037628621

VL - 1862

SP - 567

EP - 575

JO - Biochimica et Biophysica Acta - General Subjects

JF - Biochimica et Biophysica Acta - General Subjects

SN - 0304-4165

IS - 3

ER -